Vor Bio (VOR) announced that its collaborator, RemeGen reported positive 48-week results from its Phase 3 study conducted in China evaluating telitacicept in primary Sjogren’s disease. The study met its primary endpoint of change from baseline in ESSDAI at week 24, as well as all secondary endpoints, with the telitacicept 160mg dose achieving highly significant p values for every endpoint at week 24 and 48 compared to placebo. The results will be presented in the late-breaking poster session at the American College of Rheumatology, ACR, Convergence 2025 on October 28, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Largest borrow rate increases among liquid names
- Vor Bio files to sell 51M shares of common stock for holders
- Vor Bio upgraded to Buy from Hold at Stifel
- Vor Biopharma’s Strategic Moves and Telitacicept’s Potential Drive Buy Rating Amid Stock Decline
- Vor Bio appoints Khan as Chief Medical Affairs Officer